Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mechanisms and Efficacy of Camrelizumab Plus Risedronate and Chemotherapy in Triple-Negative Breast Cancer: An Exploratory Clinical Study

NCT07471815 is registered in ClinicalTrials.gov with Harbin Medical University as lead sponsor.

NCT NCT07471815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07471815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mechanisms and Efficacy of Camrelizumab Plus Risedronate and Chemotherapy in Triple-Negative Breast Cancer: An Exploratory Clinical Study
Lead sponsor
Harbin Medical University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 4, 2026
Completion date
March 31, 2029
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer triple negative breast cancer